Fibroplate Inc.

Fibroplate Inc. is a corporate entity registered in SAM.gov since 2013, specializing in advanced biomedical research and development of innovative nanosphere technologies for medical applications. The company focuses on creating cutting-edge therapeutic interventions using fibrinogen-coated albumin nanospheres (FAS), which demonstrate potential for accelerating healing processes in various medical conditions. As a for-profit organization, Fibroplate Inc. has been actively engaged in developing biomedical solutions that address complex clinical challenges, particularly in areas of wound healing, bone regeneration, and platelet-related medical complications.

Through federal grant awards from civilian agencies like the National Cancer Institute, National Institute on Aging, and National Heart Lung and Blood Institute, Fibroplate Inc. has conducted targeted research on multiple medical innovations. Their Small Business Innovation Research (SBIR) Phase I projects have explored breakthrough treatments such as accelerating surgical wound healing for breast cancer patients undergoing radiation therapy, improving bone fracture healing in elderly populations, and developing interventions for patients with platelet transfusion refractoriness. Each project demonstrates a sophisticated approach to medical research, utilizing their proprietary Fibrinoplate-S (FPS) technology to address specific clinical challenges. The grants, ranging from approximately $386,470 to undisclosed amounts, support preclinical research aimed at developing potential therapeutic agents that could significantly improve patient outcomes in oncology, geriatric medicine, and hematology. By focusing on nanosphere technologies that promote cellular mobilization and counteract inflammatory states, Fibroplate Inc. is positioning itself as an innovative biomedical research organization with potential for transformative medical solutions.